RxDoctor Payments Data

German Kamalov, MD

Cardiovascular Disease · Saint Joseph, MONPI 1225259385

Payments from drug & device makers

$19,698in general payments, 2019–2025

Across 327 payments — averaging $60.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
  • Biosense Webster, Inc.$3K
  • Boston Scientific$1K
  • Abbott$1K
  • Medical Device Business Services, Inc.$540
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$4,50023%
  • Travel & lodging$6,72034%
  • Food & beverage$8,40543%
  • Education$730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,698 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$250,031
Medicare patients
1,097
Services billed
3,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban90$114,356
EliquisApixaban126$112,727
EntrestoSacubitril/Valsartan35$41,063
Dofetilide41$8,760
Flecainide Acetate232$8,469
JardianceEmpagliflozin11$8,121
Metoprolol Succinate320$4,738
Mexiletine Hcl40$4,305
Amiodarone Hcl314$3,283
Diltiazem 24hr Er (Cd)Diltiazem Hcl102$2,600
Propafenone Hcl ErPropafenone Hcl17$1,788
Rosuvastatin Calcium166$1,723
Potassium Chloride80$1,655
Nebivolol Hcl17$1,263
ClopidogrelClopidogrel Bisulfate115$1,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$295$114,35690 claims
PfizerEliquis$63$112,727126 claims
NovartisEntresto$98$41,06335 claims
Boehringer IngelheimJardiance$72$8,12111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →